IL129768A - Organic nitrates and anticoagulants containing them - Google Patents

Organic nitrates and anticoagulants containing them

Info

Publication number: IL129768A
Authority: IL; Israel
Prior art keywords: chosen; integer; free valence; groups; carbon atoms
Prior art date: 1996-11-14

Application number

IL12976897A

Other languages

English (en)

Hebrew (he)

Other versions

IL129768A0 (en

Original Assignee

Nicox Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-14

Filing date

1997-11-12

Publication date

2004-02-19

1997-11-12 Application filed by Nicox Sa filed Critical Nicox Sa

2000-02-29 Publication of IL129768A0 publication Critical patent/IL129768A0/xx

2004-02-19 Publication of IL129768A publication Critical patent/IL129768A/en

Links

239000003146 anticoagulant agent Substances 0.000 title claims description 6
239000000203 mixture Substances 0.000 title description 8
230000002785 anti-thrombosis Effects 0.000 title description 7
229940082615 organic nitrates used in cardiac disease Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 22
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 16
230000027455 binding Effects 0.000 claims abstract description 14
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
125000001424 substituent group Chemical group 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 4
125000005717 substituted cycloalkylene group Chemical group 0.000 claims abstract description 4
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 15
229960004605 timolol Drugs 0.000 claims description 15
108010061435 Enalapril Proteins 0.000 claims description 14
229960000873 enalapril Drugs 0.000 claims description 14
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 14
-1 Moveltilpril Chemical compound 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 3
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 2
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 claims description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 claims description 2
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
108010007859 Lisinopril Proteins 0.000 claims description 2
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
229950007884 alacepril Drugs 0.000 claims description 2
229960002274 atenolol Drugs 0.000 claims description 2
229960004374 befunolol Drugs 0.000 claims description 2
ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 claims description 2
229960004530 benazepril Drugs 0.000 claims description 2
229960004324 betaxolol Drugs 0.000 claims description 2
CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 claims description 2
229960000330 bupranolol Drugs 0.000 claims description 2
229960000830 captopril Drugs 0.000 claims description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 2
229960001222 carteolol Drugs 0.000 claims description 2
229960005025 cilazapril Drugs 0.000 claims description 2
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 2
229960005227 delapril Drugs 0.000 claims description 2
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 2
229960002680 enalaprilat Drugs 0.000 claims description 2
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims description 2
229960002490 fosinopril Drugs 0.000 claims description 2
229960001195 imidapril Drugs 0.000 claims description 2
KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 2
229960001632 labetalol Drugs 0.000 claims description 2
229960002394 lisinopril Drugs 0.000 claims description 2
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
229960003134 mepindolol Drugs 0.000 claims description 2
229960004570 oxprenolol Drugs 0.000 claims description 2
229960002582 perindopril Drugs 0.000 claims description 2
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
229960001455 quinapril Drugs 0.000 claims description 2
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 2
229960004084 temocapril Drugs 0.000 claims description 2
FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 claims description 2
229960002051 trandolapril Drugs 0.000 claims description 2
IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 claims 1
108010066671 Enalaprilat Proteins 0.000 claims 1
229960004676 antithrombotic agent Drugs 0.000 claims 1
239000012659 cardioprotective agent Substances 0.000 claims 1
229940045200 cardioprotective agent Drugs 0.000 claims 1
229950005749 ceronapril Drugs 0.000 claims 1
239000005555 hypertensive agent Substances 0.000 claims 1
230000001631 hypertensive effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
239000001257 hydrogen Substances 0.000 abstract description 2
229910052739 hydrogen Inorganic materials 0.000 abstract description 2
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
239000000047 product Substances 0.000 description 27
239000000243 solution Substances 0.000 description 19
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
238000000034 method Methods 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 8
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
239000002904 solvent Substances 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
150000002828 nitro derivatives Chemical class 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
230000008569 process Effects 0.000 description 6
241000700159 Rattus Species 0.000 description 5
230000003276 anti-hypertensive effect Effects 0.000 description 5
238000011282 treatment Methods 0.000 description 5
206010006482 Bronchospasm Diseases 0.000 description 4
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
241000700198 Cavia Species 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000007885 bronchoconstriction Effects 0.000 description 4
229960002504 capsaicin Drugs 0.000 description 4
235000017663 capsaicin Nutrition 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
238000012360 testing method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
ZAEPXWFVTMAFEH-UHFFFAOYSA-N (2-hydroxyphenyl)methyl nitrate Chemical compound OC1=CC=CC=C1CO[N+]([O-])=O ZAEPXWFVTMAFEH-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
229940093499 ethyl acetate Drugs 0.000 description 3
235000019439 ethyl acetate Nutrition 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000004731 jugular vein Anatomy 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical group OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 2
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
101150041968 CDC13 gene Proteins 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001263 acyl chlorides Chemical class 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000000702 anti-platelet effect Effects 0.000 description 2
208000037849 arterial hypertension Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229960005221 timolol maleate Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
APEJDIWDAXIRHL-PPHPATTJSA-N (2s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;hydrochloride Chemical compound Cl.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 APEJDIWDAXIRHL-PPHPATTJSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
102100021587 Embryonic testis differentiation protein homolog A Human genes 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101000898120 Homo sapiens Embryonic testis differentiation protein homolog A Proteins 0.000 description 1
101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910020667 PBr3 Inorganic materials 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
241001122767 Theaceae Species 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003257 anti-anginal effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
125000002993 cycloalkylene group Chemical group 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229960000831 levobunolol Drugs 0.000 description 1
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229960002704 metipranolol Drugs 0.000 description 1
BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000000079 pharmacotherapeutic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
229960002909 spirapril Drugs 0.000 description 1
HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
108700035424 spirapril Proteins 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C203/00—Esters of nitric or nitrous acid
- C07C203/02—Esters of nitric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Materials For Medical Uses (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

IL12976897A 1996-11-14 1997-11-12 Organic nitrates and anticoagulants containing them IL129768A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT96MI002368A IT1295694B1 (it)	1996-11-14	1996-11-14	Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
PCT/EP1997/006311 WO1998021193A1 (en)	1996-11-14	1997-11-12	Antithrombotic organic nitrates

Publications (2)

Publication Number	Publication Date
IL129768A0 IL129768A0 (en)	2000-02-29
IL129768A true IL129768A (en)	2004-02-19

Family

ID=11375213

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12976897A IL129768A (en)	1996-11-14	1997-11-12	Organic nitrates and anticoagulants containing them

Country Status (18)

Country	Link
US (1)	US6242432B1 (de)
EP (1)	EP0941218B1 (de)
JP (1)	JP4264137B2 (de)
KR (1)	KR100504122B1 (de)
CN (1)	CN1094931C (de)
AT (1)	ATE226199T1 (de)
AU (1)	AU729423B2 (de)
BR (1)	BR9712959B1 (de)
CA (1)	CA2272063C (de)
DE (1)	DE69716461T2 (de)
DK (1)	DK0941218T3 (de)
ES (1)	ES2186013T3 (de)
HU (1)	HUP0000667A3 (de)
IL (1)	IL129768A (de)
IT (1)	IT1295694B1 (de)
PT (1)	PT941218E (de)
RU (1)	RU2190594C2 (de)
WO (1)	WO1998021193A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9801398D0 (en)	1998-01-22	1998-03-18	Anggard Erik E	Chemical compounds
IT1301759B1 (it) *	1998-06-19	2000-07-07	Nicox Sa	Sali nitrati di farmaci antiipertensivi
IT1311923B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IE20000052A1 (en) *	1999-04-29	2000-11-29	Russinsky Ltd	Nitric acid salts of B-blockers
IT1314184B1 (it)	1999-08-12	2002-12-06	Nicox Sa	Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AU7365900A (en)	1999-09-08	2001-04-10	Nitromed, Inc.	Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en)	1999-10-29	2007-06-26	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en)	1999-10-29	2010-05-04	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
US6635273B1 (en)	1999-10-29	2003-10-21	Trustees Of Boston University	Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en)	1999-10-29	2009-05-26	Nitromed, Inc.	Composition for treating vascular diseases characterized by nitric oxide insufficiency
JP2003523958A (ja) *	1999-12-23	2003-08-12	ニトロメドインコーポレーテッド	ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
EP1967595A3 (de)	2000-02-16	2008-12-03	Illumina, Inc.	Paralleles Genotypisieren von mehreren Patientenproben
CA2410632A1 (en)	2000-06-22	2001-12-27	David S. Garvey	Nitrosated and nitrosylated taxanes, compositions and methods of use
CA2421885A1 (en) *	2000-10-27	2002-05-02	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1219306A1 (de)	2000-12-29	2002-07-03	Nicox S.A.	Zyklodextrin und NO-abgebende Arzneimittlen enthaltende Zusammensetzungen
ATE437637T1 (de)	2001-05-02	2009-08-15	Nitromed Inc	Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
GB0111872D0 (en) *	2001-05-15	2001-07-04	Northwick Park Inst For Medica	Therapeutic agents and methods
US20080026984A1 (en) *	2002-02-04	2008-01-31	Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda	Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP2319518A1 (de)	2002-02-04	2011-05-11	ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda.	Verwendung CO-freisetzender Verbindungen zur Behandlung entzündlicher Erkrankungen
US7968605B2 (en) *	2002-02-04	2011-06-28	ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.	Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
AU2003215240A1 (en)	2002-02-14	2003-09-04	Illumina, Inc.	Automated information processing in randomly ordered arrays
US7220749B2 (en)	2002-06-11	2007-05-22	Nitromed, Inc.	Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
WO2004037843A2 (en) *	2002-10-25	2004-05-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
GB2395432B (en) *	2002-11-20	2005-09-14	Northwick Park Inst For Medica	Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
WO2004047837A2 (en) *	2002-11-22	2004-06-10	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Beta-blockers having antioxidant and nitric oxide-donor activity
WO2004050084A2 (en) *	2002-11-29	2004-06-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Ace-inhibitors having antioxidant and nitricoxid-donor activity
US20070207217A1 (en) *	2003-02-03	2007-09-06	Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda	Method for treating a mammal by administration of a compound having the ability to release CO
US7166638B2 (en)	2003-05-27	2007-01-23	Nicox S.A.	Statin derivatives
US7169805B2 (en)	2003-05-28	2007-01-30	Nicox S.A.	Captopril derivatives
WO2004110432A1 (en)	2003-06-19	2004-12-23	Nicox S.A.	Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
JP2007502831A (ja) *	2003-08-20	2007-02-15	ニトロメッドインコーポレーティッド	ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
DK1691804T3 (da) *	2003-12-02	2007-07-16	Nicox Sa	Nitrooxydderivater af carvedilol og andre beta-blokkere som antihypertensive lægemidler
JP2007513113A (ja) *	2003-12-02	2007-05-24	ニコックスエスエイ	抗高血圧薬剤のニトロオキシ誘導体
EP1704141B1 (de)	2004-01-05	2016-02-24	Nicox S.A.	Prostaglandin-nitrooxy-derivate
US20060014828A1 (en) *	2004-07-16	2006-01-19	Nitromed, Inc.	Compositions and methods related to heart failure
CA2577084A1 (en) *	2004-08-25	2006-03-02	Olivier Bezencon	Bicyclononene derivatives as renin inhibitors
EP1814535A4 (de) *	2004-11-08	2008-06-04	Nitromed Inc	Nitrosierte und nitrosylierte verbindungen, zusammensetzungen und verfahren zur behandlung von augenkrankheiten
AU2006206249A1 (en) *	2005-01-21	2006-07-27	Nicox S.A.	Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
US20100028439A1 (en) *	2005-05-23	2010-02-04	Elan Pharma International Limited	Nanoparticulate stabilized anti-hypertensive compositions
AU2006253805A1 (en) *	2005-05-27	2006-12-07	Actelion Pharmaceuticals Ltd.	Novel piperidine carboxylic acid amide derivatives
WO2007000641A2 (en) *	2005-06-29	2007-01-04	Pfizer Inc.	Prostaglandin derivatives
JP2009514809A (ja) *	2005-10-18	2009-04-09	ニコックスエスエイ	レニン阻害剤のニトロ誘導体
GB0601394D0 (en)	2006-01-24	2006-03-01	Hemocorm Ltd	Therapeutic delivery of carbon monoxide
RU2425032C2 (ru)	2006-02-02	2011-07-27	Актелион Фармасьютикалз Лтд	Вторичные амины в качестве ингибиторов ренина
AU2007217980A1 (en) *	2006-02-17	2007-08-30	Nitromed, Inc.	Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
NZ571595A (en) *	2006-03-08	2010-06-25	Actelion Pharmaceuticals Ltd	New amines
JP2007275193A (ja) *	2006-04-04	2007-10-25	Fujifilm Corp	光プローブおよび光断層画像化装置
AU2007254283A1 (en) *	2006-05-16	2007-11-29	Nitromed, Inc.	Solid dosage formulations of hydralazine compounds
RU2322972C1 (ru) *	2006-09-12	2008-04-27	Илья Николаевич Медведев	Способ профилактики тромбозов у больных артериальной гипертонией с метаболическим синдромом
TW200831079A (en) *	2006-12-13	2008-08-01	Merck & Co Inc	Angiotensin II receptor antagonists
FR2921365B1 (fr) *	2007-09-21	2012-10-12	Servier Lab	Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8889714B2 (en) *	2008-05-05	2014-11-18	Actelion Pharmaceuticals Ltd.	3,4-substituted piperidine derivatives as renin inhibitors
WO2010116270A1 (en)	2009-04-10	2010-10-14	Pfizer Inc.	Ep2/4 agonists
WO2011160974A2 (en)	2010-06-21	2011-12-29	Nicox S.A.	Statin derivatives
PT2699242T (pt)	2011-04-19	2018-01-22	Alfama Inc	Moléculas de libertação de monóxido de carbono e utilizações das mesmas
ES2628634T3 (es)	2011-07-21	2017-08-03	Alfama, Inc.	Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
US9844599B2 (en)	2013-01-21	2017-12-19	Apparao Satyam	Nitric oxide releasing produgs of therapeutic agents
JP7055802B2 (ja)	2016-11-08	2022-04-18	ボシュ・アンド・ロム・インコーポレイテッド	正常眼圧緑内障を処置するための一酸化窒素放出プロスタグランジン誘導体
DK3993876T3 (en)	2019-07-01	2024-12-02	Tonix Pharma Ltd	Anti-cd154 antibodies and uses thereof
AU2022205313A1 (en)	2021-01-06	2023-07-20	Tonix Pharma Limited	Methods of inducing immune tolerance with modified anti-cd154 antibodies
CN118146175A (zh) *	2024-02-07	2024-06-07	广州楷石生物科技有限公司	右旋噻吗洛尔衍生物及其制备方法和应用
WO2025248134A1 (en)	2024-05-31	2025-12-04	Tonix Pharma Limited	Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1256345B (it)	1992-08-20	1995-12-01		Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it)	1992-11-26	1995-12-05	Soldato Piero Del	Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
ES2065291B1 (es) *	1993-07-30	1995-10-01	Prodesfarma Sa	"nitrato esteres de 1-ariloxi-3-alquilamino-2-propanoles, utilizacion y composicion farmaceutica correspondiente"
JP3775796B2 (ja)	1993-10-06	2006-05-17	ニコックスエスエイ	抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
RU2145595C1 (ru) *	1994-05-10	2000-02-20	Никокс С.А.	Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
AU2230897A (en) *	1996-03-01	1997-09-16	Sankyo Company Limited	Thiazolidine derivatives

1996
- 1996-11-14 IT IT96MI002368A patent/IT1295694B1/it active IP Right Grant
1997
- 1997-11-12 JP JP52217998A patent/JP4264137B2/ja not_active Expired - Fee Related
- 1997-11-12 PT PT97951890T patent/PT941218E/pt unknown
- 1997-11-12 AT AT97951890T patent/ATE226199T1/de active
- 1997-11-12 IL IL12976897A patent/IL129768A/en not_active IP Right Cessation
- 1997-11-12 BR BRPI9712959-3A patent/BR9712959B1/pt not_active IP Right Cessation
- 1997-11-12 EP EP97951890A patent/EP0941218B1/de not_active Expired - Lifetime
- 1997-11-12 WO PCT/EP1997/006311 patent/WO1998021193A1/en not_active Ceased
- 1997-11-12 CN CN97181245A patent/CN1094931C/zh not_active Expired - Fee Related
- 1997-11-12 ES ES97951890T patent/ES2186013T3/es not_active Expired - Lifetime
- 1997-11-12 CA CA002272063A patent/CA2272063C/en not_active Expired - Fee Related
- 1997-11-12 KR KR10-1999-7004229A patent/KR100504122B1/ko not_active Expired - Fee Related
- 1997-11-12 RU RU99112517/04A patent/RU2190594C2/ru not_active IP Right Cessation
- 1997-11-12 DE DE69716461T patent/DE69716461T2/de not_active Expired - Lifetime
- 1997-11-12 AU AU55519/98A patent/AU729423B2/en not_active Ceased
- 1997-11-12 US US09/297,933 patent/US6242432B1/en not_active Expired - Fee Related
- 1997-11-12 HU HU0000667A patent/HUP0000667A3/hu unknown
- 1997-11-12 DK DK97951890T patent/DK0941218T3/da active

Also Published As

Publication number	Publication date
ES2186013T3 (es)	2003-05-01
IL129768A0 (en)	2000-02-29
AU5551998A (en)	1998-06-03
DE69716461D1 (de)	2002-11-21
KR20000053251A (ko)	2000-08-25
JP4264137B2 (ja)	2009-05-13
JP2001507676A (ja)	2001-06-12
ITMI962368A1 (it)	1998-05-14
US6242432B1 (en)	2001-06-05
KR100504122B1 (ko)	2005-07-27
AU729423B2 (en)	2001-02-01
DE69716461T2 (de)	2003-06-26
CA2272063A1 (en)	1998-05-22
IT1295694B1 (it)	1999-05-27
BR9712959A (pt)	2000-02-01
ITMI962368A0 (it)	1996-11-14
BR9712959B1 (pt)	2010-06-01
ATE226199T1 (de)	2002-11-15
DK0941218T3 (da)	2003-02-17
CN1094931C (zh)	2002-11-27
EP0941218B1 (de)	2002-10-16
RU2190594C2 (ru)	2002-10-10
WO1998021193A1 (en)	1998-05-22
HUP0000667A2 (en)	2000-07-28
PT941218E (pt)	2003-03-31
HUP0000667A3 (en)	2000-08-28
EP0941218A1 (de)	1999-09-15
CN1242768A (zh)	2000-01-26
CA2272063C (en)	2008-05-27

Legal Events

Date	Code	Title
2004-07-25	FF	Patent granted
2008-01-06	KB	Patent renewed
2012-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US6242432B1 (en)	2001-06-05	Antithrombotic organic nitrates
EP1653950B1 (de)	2008-01-09	Nitrooxyderivate von losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan als angiotensin-ii-rezeptor-blocker zur behandlung von herz-kreislauf-erkrankungen
CA1288547C (en)	1991-09-03	1-(3-mercapto-2-methylpropanoyl) prolyl amino acid derivatives and salts thereof, processes for their preparation and pharmaceutical compositions containing such compounds
CA2183315C (en)	1999-08-31	Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
IL91460A (en)	1995-08-31	Cycloalkyl-substituted glutaramide antihypertensive agents
PT101027A (pt)	1994-02-28	Peptideos, processo para a sua preparacao e sua utilizacao como compostos farmaceuticos
SK63194A3 (en)	1994-12-07	Peptide derivatives
WO1997037969A1 (en)	1997-10-16	Tryptase inhibitor and novel guanidino derivatives
JPH08502971A (ja)	1996-04-02	ファルネシル−タンパク質トランスフェラーゼの阻害剤
WO1994006756A1 (en)	1994-03-31	N-(acylaminomethyl)glutaryl amino acids and their use as dual inhibitors of neutral endopeptidase and angiotensin converting enzyme
US20030021773A1 (en)	2003-01-30	Arginine mimetics as factor Xa inhibitors
WO2000058346A1 (fr)	2000-10-05	Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique
CA2092414A1 (en)	1992-04-12	N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
JPH01250345A (ja)	1989-10-05	非ペプチド性レニン阻害剤
EP0159156A1 (de)	1985-10-23	Hydroxy-substituierte Ureidoamino- und -iminosäuren
EP1635816B1 (de)	2009-03-04	Enalapril-nitroxy-derivate und verwandte verbindungen als ace-hemmer zur behandlung von kardiovaskulären erkrankungen
Doherty et al.	1991	New inhibitors of human renin that contain novel replacements at the P2 site
IE60205B1 (en)	1994-06-15	Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
IE910083A1 (en)	1991-07-17	Cycloalkyl-substituted glutaramide diuretic agents
JPH0848664A (ja)	1996-02-20	新規なグアニジノ安息香酸エステル誘導体
MXPA96003347A (en)	1998-09-18	Derivatives of 1,3,5,5-tetrahydro-benzo [c] azepin-3-ona mercaptoacetilamido novedosos, useful as inhibitors of encephalinase and convertible enzyme of angiotens
JPH07173127A (ja)	1995-07-11	ヒドロキサム酸誘導体およびそれを有効成分とするエラスターゼ阻害剤
JPH0940631A (ja)	1997-02-10	アミジノフェノール誘導体、その製造方法およびダニアレルギー治療剤
BG64156B1 (bg)	2004-02-27	Нови n-ацилни производни на пиперазина с антихипертензивна активност и метод за тяхното получаване
JPH07173061A (ja)	1995-07-11	β−ケト酸誘導体およびそれを有効成分とするエラスターゼ阻害剤